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Abstract
Background: In this study, we investigated whether PKR protein expression is correlated with mRNA levels and also
evaluated molecular biomarkers that are associated with PKR, such as phosphorylated PKR (p-PKR) and phosphorylated
eIF2a (p-eIF2a).
Methodology and Findings: We determined the levels of PKR protein expression and mRNA in 36 fresh primary lung tumor
tissues by using Western blot analysis and real-time reverse-transcriptase PCR (RT-PCR), respectively. We used tissue
microarrays for immunohistochemical evaluation of the expression of p-PKR and p-eIF2a proteins. We demonstrated that
PKR mRNA levels are significantly correlated with PKR protein levels (Spearman’s rho=0.55, p,0.001), suggesting that PKR
protein levels in tumor samples are regulated by PKR mRNA. We also observed that the patients with high p-PKR or p-eIF2a
expression had a significantly longer median survival than those with little or no p-PKR or p-eIF2a expression (p=0.03 and
p=0.032, respectively). We further evaluated the prognostic effect of combined expression of p-PKR plus PKR and p-eIF2a
plus PKR and found that both combinations were strong independent prognostic markers for overall patient survival on
stage I and all stage patients.
Conclusions: Our findings suggest that PKR protein expression may controlled by transcription level. Combined expression
levels of PKR and p-PKR or p-eIF2a can be new markers for predicting the prognosis of patients with NSCLC.
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Introduction
The protein kinase (PKR) is an interferon-inducible serine/
threonine kinase that mediates protein synthesis, a tightly regu-
lated process that is critical in cellular proliferation and diffe-
rentiation [1–3]. Increased PKR expression has been shown to
correlate with better prognoses in head and neck cancer and colon
cancer [2,3], and accumulating evidence demonstrates that
PKR may act as a tumor suppressor in leukemia and other
hematopoietic malignancies [4,5]. Binding of either double-
stranded RNA (dsRNA) or structured single-stranded RNAs can
mediate PKR phosphorylation [6,7]. Activated PKR phosphory-
lates its well-documented downstream target, the alpha subunit
of protein synthesis initiation factor eIF2 (eIF2a), leading to
inhibition of protein synthesis and eliciting antiviral and antitumor
activities [8,9]. In addition to its role in translational control, PKR
has been implicated in antiviral innate immunity, apoptosis, cell
proliferation, and stress signaling [10]. Moreover, PKR expression
and autophosphorylation are increased in several types of cancer,
including melanoma, colon cancer, and breast cancer [11,12]. The
results of several studies have demonstrated the importance of
phosphorylated eIF2a (p-eIF2a) in cancer therapy [10,13,14]:
activation of the PKR-eIF2a phosphorylation pathway is essential
for the antiproliferative and proapoptotic functions of the tumor
suppressor gene [15].
Recently, we found that low expression of dsRNA-dependent
PKR was significantly associated with shorter survival in NSCLC
patients, suggesting that biologic functions of PKR or its
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e24855downstream molecules could be valuable prognostic factors in
NSCLC [1]. In this new study, our goal was to determine whether
PKR protein expression is associated with its mRNA levels and
whether its downstream targets, such as phosphorylated PKR (p-
PKR) and p-eIF2a, are also prognostic factors in NSCLC. We first
determined the PKR mRNA levels and protein expression in
fresh-frozen NSCLC tissue and found a positive correlation
between PKR protein expression and mRNA levels. Next, using
immunohistochemical staining, we investigated the expression of
p-PKR and its well-characterized downstream molecule p-eIF2a
in archived tissue microarray specimens. Our results show that p-
PKR and p-eIF2a are predictive biomarkers of NSCLC outcomes
and that when expression of PKR was combined with expression
of p-PKR or p-eIF2a, the effect on predicting patient survival was
enhanced.
Results
PKR protein expression correlates with mRNA levels
To investigate whether PKR protein expression is associated
with mRNA levels, we determined the PKR and p-PKR protein
expression and PKR mRNA levels in 36 fresh primary lung tumor
tissues using Western blot analysis and real time RT-PCR,
respectively. Protein expression of b-actin and its mRNA levels
were also determined and used as controls. The results of the
Western blotting analyses showed that tumor samples expressed
different levels of PKR at both protein and mRNA levels
(Figure 1A and 1B). Statistical analysis revealed a significant
correlation between PKR protein expression and its mRNA levels.
(Spearman’s rho=0.55, p,0.001; Figure 1C). These results
suggest that PKR gene expression may cause of the differing
levels of PKR protein expression in tumors.
Correlation between p-PKR and p-eIF2a protein
expression in NSCLC tumors with clinicopathologic
features
Because the biological function of PKR is closely associated with
its phosphorylation, and eIF2a phosphorylation is a hallmark of
PKR activation, we next evaluated the expression of p-PKR and
p-eIF2a proteins in TMA specimens using immunohistochemical
staining. Table 1 summarizes the relationships between p-PKR or
p-eIF2a expression and other clinicopathologic features. High p-
PKR expression was associated with the adenocarcinomas subtype
Figure 1. PKR mRNA levels are correlated with PKR protein levels in primary NSCLC tissues. A. Western blot analysis of PKR and p-PKR
protein in tumor samples. A densitometric analysis of the ratio of PKR or PKR to b-actin is represents normalized protein levels. Each lane represents a
tumor sample from an individual patient. B. mRNA levels of corresponding samples were determined using quantitative real-time PCR. Levels of b-
actin protein and its mRNA of the same sample were used as controls. C. Scatter plot of PKR protein expression correlated with mRNA expression
(Spearman’s rho=0.55, p,0.001).
doi:10.1371/journal.pone.0024855.g001
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sion and gender sex, TNM stage, or smoking status. We also found
no correlation between p-eIF2a expression and clinicopathologic
features. Representative images of immunohistochemical staining
results for p-PKR and p-eIF2a are shown in Figure 2. The p-PKR
and p-eIF2a proteins were expressed in the cytoplasm of tumor
cells.
Correlation between p-PKR and p-eIF2a protein
expression in NSCLC tumors with disease outcomes
To further evaluate whether p-PKR or p-eIF2a protein
expression correlates with clinical outcomes of patients with
NSCLC, Kaplan–Meier analysis revealed that for stage I and all
stages, patients with relatively elevated p-PKR had significantly
longer survival than those with little or no p-PKR expression
(Figure 3A and 3C). For all stage patients, the median survival
time was 105 months for patients with high p-PKR expression and
51 months for those with little or no p-PKR expression. A
significant association was also observed between high p-eIF2a
protein expression and longer survival on stage I and all stages
(Figure 3D and 3F). There is no significant association was
observed between high p-PKR or high p-eIF2a protein expression
and longer survival on stages II–IV (Figure 3B and 3E).
In a univariate analysis, a Cox proportional hazards model
indicated that p-PKR and p-eIF2a had prognostic significance
(Table 2). In a multivariate analysis, we found that p-PKR and p-
eIF2a expression were statistically significant associated with
survival (Table 2). These results indicate that p-PKR and p-eIF2a
expression are independent biomarkers of patients’ survival.
We also examined the associations between the expression levels
of PKR, p-PKR, and p-eIF2a. Our results indicated that p-PKR
expression significantly correlated with p-eIF2a expression (Spear-
man’s rho=0.48, p,0.001). PKR expression also significantly
correlated with expression of p-PKR (Spearman’s rho=0.31,
p=0.004) and p-eIF2a (Spearman’s rho=0.45, p,0.001). We
further evaluated the prognostic effect of combined expression of
p-PKR plus PKR and p-eIF2a plus PKR and found that both
combinations were strong independent prognostic markers for
overall patient survival on stage I (Figure 4A and 4B) and all stage
patients (Figure 4C and 4D). For all stage patients, patients with
high PKR and high p-PKR expression had a median survival time
of 132 months, which was significantly longer than that of patients
Table 1. Relationships between the level of p-PKR and p-eIF2a expression and clinicopathologic characteristics in TMA of NSCLC
patients.
Characteristics p-PKR Score p-Value p-eIF2a Score p-Value
Low (,=70) High (.70) Low (,=150) High (.150)
Gender 0.11 0.45
Male 49 (50.0) 34 (37.6) 39 (43.3) 44 (49.4)
Female 49 (50.0) 56 (62.4) 51 (56.7) 45 (50.6)
Pathological TNM 0.33
a 0.25
a
Stage I 62 (62.9) 58 (64.4) 55 (60.0) 57 (64.8)
Stag II 19 (19.6) 13 (14.4) 17 (18.9) 16 (18.2)
Stage III–IV 17 (17.5) 19 (21.2) 19 (21.1) 15 (17.0)
pT 0.11
b 0.46
b
T1 26 (26.5) 35 (38.9) 27 (30.1) 30 (33.7)
T2 64 (65.3) 47 (52.2) 56 (62.2) 48 (53.9)
T3 3 (3.1) 5 (5.6) 3 (3.3) 6 (6.8)
T4 5 (5.1) 3 (3.3) 4 (4.4) 5 (5.6)
pN 0.48
c 0.06
c
N0 67 (68.4) 62 (68.9) 57 (63.3) 67 (75.3)
N1 20 (20.4) 13 (15.4) 19 (21.1) 14 (15.7)
N2 11 (11.2) 14 (15.7) 14 (15.6) 8 (9.0)
pM 0.07 0.36
M0 96 (97.9) 84 (93.3) 86 (95.5) 86 (96.6)
M1 2 (2.1) 6 (6.7) 4 (4.4) 3 (3.4)
Histologic type ,0.01 0.19
ACC 41 (41.4) 73 (82.0) 51 (56.7) 56 (62.5)
SCC 58 (58.6) 16 (18.0) 39 (43.3) 33 (37.5)
Tobacco history 0.11 0.13
No 25 (25.5) 33 (36.3) 29 (32.2) 19 (21.8)
Yes 72 (74.5) 58 (63.7) 61 (67.8) 68 (78.2)
aThe p-value was calculated between pathologic stage I and II–IV.
bBetween T1 and T2–T4.
cBetween N0 and N1–N2.
SCC, squamous cell carcinoma. ACC, Adenocarcinoma.
doi:10.1371/journal.pone.0024855.t001
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PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e24855Figure 2. Representative results of immunohistochemical staining of NSCLC tumor specimens for p-PKR and p-eIF2a. High-expressing
cases (A and C). Low-expressing cases (B and D). Expression of p-PKR and p-eIF2a was detected in the cytoplasm.
doi:10.1371/journal.pone.0024855.g002
Figure 3. The prognostic significance assessed by using Kaplan-Meier survival estimates and long-rank test. A–F. Kaplan-Meier
survival curves according to the differences in (A, B, C) p-PKR and (D, E, F) p-eIF2-a expression in patients with stage I (A, D), stages II–IV (B, E) and all
stage (C, F) NSCLC. The survival rates were significantly worse in the patients with low p-PKR or p-eIF2a expression than in those with high p-PKR or
p-eIF2a expression (Stage I: p=0.01 and p=0.02; All stages: p=0.03 and p=0.03, respectively).
doi:10.1371/journal.pone.0024855.g003
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months; Figure 4C). Patients with little or no PKR and p-PKR
expression had a significantly shorter median survival (43 months;
Figure 4C). There is a difference in outcome for PKR(H)/p-
PKR(H) vs PKR(L)/p-PKR(H) patients on Figure 4A. Our IHC
score range is 0–300 for PKR and p-PKR. In current study, we
are using median cut-off (150 for PKR and 70 for p-PKR). On
Figure 4A, 106 stage I patients divided into four groups, 43
patients with high PKR and high p-PKR, 21 patients with high
PKR and low p-PKR expression, 32 Patients with low PKR and
p-PKR expression and 10 patients with low PKR and high p-PKR
expression. These 10 patients have p-PKR score range 80–120,
are very close to median cut-off score (70), and may also belong to
low PKR low p-PKR group. For all stage patients, patients with
high PKR and high p-eIF2a expression had a median survival
time of 132 months, which was significantly longer than that of
patients with high PKR plus low p-eIF2a expression (median
survival, 80 months) and those with low PKR plus high p-eIF2a
expression (median survival, 47 months; Figure 4D). Finally,
patients with little or no expression of both PKR and p-eIF2a had
a significantly short median survival (median survival, 35 months;
Figure 4D).
Discussion
The results of this study show that PKR mRNA levels are
associated with PKR protein expression in primary NSCLC
tumors. Our findings suggest that PKR protein expression may
control transcription levels. Further, our data suggest that real time
RT-PCR, a sensitive method for quantitatively analyzing mRNA
levels, can be used to determine mRNA levels in biopsy samples
and might therefore be useful for predicting patient survival.
We also found that patients with high p-PKR expression had
significantly longer median survival than those with little or no p-
PKR protein expression. Results of various studies of human
malignancies have suggested that high PKR expression indicates
favorable prognosis for patients with squamous cell carcinoma of
the head or liver [2,16], thus suggesting that PKR may play an
important role in suppressing tumor progression and affecting
apoptosis [17]. We have also studied PKR pathways and have
found them to be clearly necessary for inducing apoptosis in some
cancer cells, including lung cancer, after certain treatments such as
melanoma differentiation-associated gene 7 (MDA7), E2F-1, and
TNFa [18,19]. More recently, we and others demonstrated that
some small compounds can induce PKR-dependent apoptosis in
both cancer cells and murine embryonic fibroblasts [20,21],
indicating that modulating PKR activity could be an interesting
approach to cancer therapy. Our finding that NSCLC tumor cells
that express a high level of p-PKR correlate with a favorable
prognosis is consistent with previous observations that PKR
activation is associated with apoptosis induction.
Our findings also demonstrated that patients with high
expression of both PKR and p-PKR had significantly longer
survival than did those with other combinations of expression
levels, including those positive for PKR and negative for p-PKR
and those negative for both PKR and p-PKR. Our observation
that 53% of the NSCLC tumor samples highly expressed PKR
and that 61% of them highly expressed p-PKR [data not shown]
These results led us to speculate that PKR expression (i.e., PKR)
and PKR activation (i.e., p-PKR) are affected by differing
expression of the PKR activator or PKR inhibitor. Other
investigators have reported that the function of PKR can be
regulated by cellular proteins either positively (e.g., MDA-7/
interleukin-24 and PKR-activating protein [PACT]) or negatively
(e.g., p58IPK, nucleophosmin and heat shock proteins 90 and 70)
[18,19]. In future studies, we will seek to determine which PKR
activators and inhibitors affect the PKR signaling pathway in
NSCLC tumor samples.
We observed that tumors with high p-eIF2a expression had a
significantly longer median survival. In additional, we demon-
strated that patients with high expressions of both PKR and p-
eIF2a also had significantly longer survival than did those with
other combinations of expression levels. Our finding that 47% of
the tumor samples had low PKR expression and 27% had high p-
eIF2a expression [data not shown]. These results suggest that
eIF2a phosphorylation in some NSCLC tumors occurs indepen-
dent of the PKR pathway. Besides PKR, three different eIF2a
kinases that can phosphorylate eIF2a in response to various stress
Table 2. Univariate and multivariate Cox model assessing effects of covariates on overall survival.
Stage I All Stages
Characteristics Hazard ratio (95% CI) p-Value Hazard ratio (95% CI) p-Value
A. Univariate Cox regression model
Age 0.99 (0.99–1.00) 0.21 0.99 (0.96–1.02) 0.48
Gender (male vs female) 1.49 (0.88–2.51) 0.14 1.31 (0.87–1.96) 0.19
Tobacco history (yes vs no) 1.50 (0.78–2.89) 0.22 0.85 (0.54–1.33) 0.48
Pathological TNM stage
Stage II+III+IV vs I - - 2.79 (1.65–4.71) 0.001
Histologic type (ACC vs SCC) 1.36 (0.67–2.78) 0.39 2.00 (0.58–6.85) 0.27
p-PKR (High vs Low) 0.45 (0.24–0.84) 0.01 0.51 (0.28–0.96) 0.02
p-eIF2a (High vs Low) 0.53 (0.31–0.92) 0.03 0.54 (0.32–0.96) 0.03
B. Multivariate Cox regression model
Pathological TNM stage
Stage II+III+IV vs I - - 2.71 (1.53–4.82) 0.001
p-PKR (High vs Low) - - 0.56 (0.34–0.95) 0.03
p-eIF2a (High vs Low) - - 0.61 (0.42–0.97) 0.04
doi:10.1371/journal.pone.0024855.t002
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homologue of Saccharomyces cerevisiae protein kinase general control
non-derepressible-2, and RNA-dependent-protein-kinase-like en-
doplasmic reticulum (ER) kinase (PERK; also known as pancreatic
eIF2a kinase) [13].
In conclusion, our data suggest that the PKR/phosphorylated
PKR/phosphorylated eIF2a signaling pathway plays an important
role in the prognosis for non-small cell lung cancer (NSCLC).
PKR pathway activities may be useful for predicting NSCLC
outcomes, and modulating PKR pathway activities might be a
potential NSCLC treatment option.
Methods
Patients and Tissues
NSCLC patients who were undergoing radical resection of their
primary cancer at The University of Texas M. D. Anderson
Cancer Center between 2007 and 2008 were used for this study
based on availability. Patients were excluded from the study if they
had previously undergone radiotherapy or chemotherapy for
cancer. Patients all provided written informed consent for the use
of their tissues, and the study was approved by our Institutional
Review Board (University of Texas, MD Anderson Cancer
Center). After being surgically resected, each fresh tumor was
immediately divided into two portions; one was instantly frozen
and stored in liquid nitrogen for protein and RNA extraction, and
the other was fixed with formalin and embedded in paraffin for
routine histopathologic evaluation and diagnosis. Tissues with
an estimated tumor cell content of 70% or more were used
for molecular analyses. In addition to our patients’ tissues, we
obtained 193 NSCLC Tissue microarray (TMA) specimens (114
adenocarcinomas, and 74 squamous cell carcinomas) between
1997 and 2001 from the Lung Cancer Specialized Program of
Research Excellence Tissue Bank at M. D. Anderson Cancer
Center (Houston, TX). All specimens were histologically examined
and classified using the 2004 World Health Organization
classification system [22]. In most cases, detailed clinical and
pathologic information, including the patients’ demographic data,
smoking history, and overall survival plus the disease TNM staging
and time to recurrence, was available (Table 1).
Western Blot Analysis
Frozen tumor tissues were initially preparared by being washed
twice in cold PBS. Approximately 20 mg of tissue from each fresh
sample was homogenized in 0.5 ml ice-cold lysis buffer (1% NP40,
50 mM HEPES [pH 7.4], 150 mM NaCl, 1.5 mM MgCl2,
Figure 4. The prognostic significance assessed by using Kaplan-Meier survival estimates and long-rank test. A and C. Survival rate was
significantly lower patients with low PKR or low p-PKR expression than in those with high PKR or high p-PKR expression on stage I (A) and all stages
(C) (p=0.001 and p=0.001, respectively). B and D. Survival rate was also significantly lower in patients with low PKR or low p-eIF2a expression than in
those with high PKR or high p-eIF2a expression on stage I (B) and all stages (D) (p=0.001 and p=0.001, respectively).
doi:10.1371/journal.pone.0024855.g004
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10 mM Na pyrophosphate [Roche Applied Science]), containing
freshly added protease and phosphate inhibitor. The lysates were
spun at 14,000 g in a microcentrifuge at 4uC for 10 min, and the
resulting supernatants were used as tissue extracts. The extracts,
equivalent to 60 mg of the total protein, were separated by using a
10% SDS-polyacrylamide gel and then transferred to nitro-
cellulose membranes. The membranes were blocked with TBS
containing 5% nonfat dried milk and then probed in PBS
containing 5% bovine serum. The following antibodies were used:
rabbit anti-PKR (K-17; Santa Cruz Biotechnology), rabbit anti-p-
PKR (pT446) (Epitomics), rabbit anti-p-eIF2a (Epitomics), and
mouse anti-b-actin (Sigma). Immunoreactive bands were detected
and quantified using a Li-Cor Odyssey infrared imaging system.
Reverse Transcription and Real-time Absolute
Quantitative Reverse-Transcription-Polymerase Chain
Reaction (Real-Time AqRT-PCR)
The total RNA (1 mg) from each frozen clinical sample was
extracted using a Trizol extraction kit (Invitrogen) and reverse
transcribed in a 20 mL reaction volume by using Taqman re-
verse-transcription reagents (Applied Biosystems) according to
the manufacturer’s instructions. The cDNAs were diluted and
quantified for expression PKR using real-time RT-PCR (SYBR
Green I) (performed by Ziren Research LLC, Irvine, CA). A single
standard was incorporated to determine the absolute ratio of
expression of each target and reference gene, as previously
described [23]. The primer sequences for PKR were as follows:
forward, 59-TCTTCATGTATGTGACACTGC-39, and reverse,
59-CACACAGTCAAGGTCCTT AG-39.
Immunohistochemical Staining and Evaluation
The antibodies used for Western blot analysis were also used for
immunohistochemical staining. Formalin-fixed and paraffin-em-
bedded tissue histology sections (5-mm thick) were deparaffinized,
hydrated and heated in a steamer for 10 min with 10 mmol/L of
sodium citrate (pH 6.0) for antigen retrieval. Peroxidase was
blocked with 3% H2O2 in methanol at room temperature for
15 min, followed by incubation in 10% bovine serum albumin in
TBS-t for 30 min. The slides were next incubated with primary
antibody at 1:100 dilutions for 65 min at room temperature. After
being washed with PBS, the slides were incubated with biotin-
labeled secondary antibody for 30 min. Finally, the samples were
incubated with streptavidin-peroxidase at a 1:40 dilution for
30 min. The samples were then stained with 0.05% 39,3 -
diaminobenzidine tetrahydrochloride prepared in 0.05 mol/L of
Tris buffer (pH 7.6) containing 0.02% H2O2 and subsequently
counterstained with hematoxylin. As a positive control, formalin-
fixed and paraffin-embedded lung tissues with normal bronchial
epithelia were used. As a negative control, tissue samples not
incubated with the primary antibody were used. Immunohisto-
chemical staining was quantified by two independent pathologists
(Drs. Raso and Pataer) with a four-value intensity score described
previously [1].
Statistical Analysis
The median was used as the cutoff point for p-PKR and p-
eIF2a. The biomarkers were dichotomized into low- and high-
level groups as follows: p-PKR: low (score#70), high (score.70);
and p-eIF2a: low (score#150), high (score.150). In univariate
analysis, independent sample t and X
2 tests were used to analyze
continuous and categorical variables, respectively. Survival
probability as a function of time was computed by using the
Kaplan-Meier estimator. The log-rank test was used for between-
group comparisons of patient survival time. The Cox proportional
hazards model was used to calculate the influence of p-PKR and
p-eIF2a expression on survival time, with adjustments made for
clinical and histopathologic parameters (age, sex, smoking status
and tumor histologic subgroup. The two-sided test was used to test
equal proportion between groups in two-way contingency tables.
The generalized estimating equation approach was used to
estimate differences in the means for the data. Statistical
significance was set at P,0.05.
Acknowledgments
We thank Markeda Wade for editorial review. We thank Denise M. Woods
and Lakshimi Kakarala for their technical assistance.
Author Contributions
Conceived and designed the experiments: YH AP SS. Performed the
experiments: YH AP MR YZ LY. Analyzed the data: AP AC. Contributed
reagents/materials/analysis tools: IW CB JR BF WH. Wrote the paper:
YH AP.
References
1. Pataer A, Raso MG, Correa AM, Behrens C, Tsuta K, et al. (2010) RNA-
dependent protein kinase is an independent prognostic variable for non-small
cell lung cancer patients. Clin Cancer Res 16: 5522–5528.
2. Haines GK, 3rd, Becker S, Ghadge G, Kies M, Pelzer H, et al. (1993)
Expression of the double-stranded RNA-dependent protein kinase (p68) in
squamous cell carcinoma of the head and neck region. Arch Otolaryngol Head
Neck Surg 119: 1142–1147.
3. Singh C, Haines GK, Talamonti MS, Radosevich JA (1995) Expression of p68
in human colon cancer. Tumour Biol 16: 281–289.
4. Li S, Koromilas AE (2001) Dominant negative function by an alternatively
spliced form of the interferon-inducible protein kinase PKR. J Biol Chem 276:
13881–13890.
5. Hii SI, Hardy L, Crough T, Payne EJ, Grimmett K, et al. (2004) Loss of PKR
activity in chronic lymphocytic leukemia. Int J Cancer 109: 329–335.
6. Bilanges B, Stokoe D (2007) Mechanisms of translational deregulation in human
tumors and therapeutic intervention strategies. Oncogene 26: 5973–5990.
7. Holland EC, Sonenberg N, Pandolfi PP, Thomas G (2004) Signaling control of
mRNA translation in cancer pathogenesis. Oncogene 23: 3138–3144.
8. Hovanessian AG (1989) The double stranded RNA-activated protein kinase
induced by interferon: dsRNA-PK. J Interferon Res 9: 641–647.
9. Williams BR (2001) Signal integration via PKR. Sci STKE 2001: re2.
10. Toth AM, Zhang P, Das S, George CX, Samuel CE (2006) Interferon action
and the double-stranded RNA-dependent enzymes ADAR1 adenosine
deaminase and PKR protein kinase. Prog Nucleic Acid Res Mol Biol 81:
369–434.
11. Kim SH, Forman AP, Mathews MB, Gunnery S (2000) Human breast cancer
cells contain elevated levels and activity of the protein kinase, PKR. Oncogene
19: 3086–3094.
12. Kim SH, Gunnery S, Choe JK, Mathews MB (2002) Neoplastic progression in
melanoma and colon cancer is associated with increased expression and activity
of the interferon-inducible protein kinase, PKR. Oncogene 21: 8741–8748.
13. Schewe DM, Aguirre-Ghiso JA (2009) Inhibition of eIF2alpha dephosphoryla-
t i o nm a x i m i z e sb o r t e z o m i be f f i c i e n c ya n de l i m i n a t e sq u i e s c e n tm u l t i p l e
myeloma cells surviving proteasome inhibitor therapy. Cancer Res 69:
1545–1552.
14. Zhu K, Chan W, Heymach J, Wilkinson M, McConkey DJ (2009) Control of
HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational
repression. Cancer Res 69: 1836–1843.
15. Mounir Z, Krishnamoorthy JL, Robertson GP, Scheuner D, Kaufman RJ, et al.
(2009) Tumor suppression by PTEN requires the activation of the PKR-
eIF2alpha phosphorylation pathway. Sci Signal 2: ra85.
16. Shimada A, Shiota G, Miyata H, Kamahora T, Kawasaki H, et al. (1998)
Aberrant expression of double-stranded RNA-dependent protein kinase in
hepatocytes of chronic hepatitis and differentiated hepatocellular carcinoma.
Cancer Res 58: 4434–4438.
17. Vorburger SA, Pataer A, Swisher SG, Hunt KK (2004) Genetically targeted
cancer therapy: tumor destruction by PKR activation. Am J Pharmacogenomics
4: 189–198.
18. Pataer A, Vorburger SA, Barber GN, Chada S, Mhashilkar AM, et al. (2002)
Adenoviral transfer of the melanoma differentiation-associated gene 7 (mda7)
Prognostic Value of P-PKR and P-eIF2a
PLoS ONE | www.plosone.org 7 November 2011 | Volume 6 | Issue 11 | e24855induces apoptosis of lung cancer cells via up-regulation of the double-stranded
RNA-dependent protein kinase (PKR). Cancer Res 62: 2239–2243.
19. D’Acquisto F, Ghosh S (2001) PACT and PKR: turning on NF-kappa B in the
absence of virus. Sci STKE 2001: re1.
20. Hu W, Hofstetter W, Wei X, Guo W, Zhou Y, et al. (2009) Double-stranded
RNA-dependent protein kinase-dependent apoptosis induction by a novel small
compound. J Pharmacol Exp Ther 328: 866–872.
21. Trisciuoglio D, Uranchimeg B, Cardellina JH, Meragelman TL, Matsunaga S,
et al. (2008) Induction of apoptosis in human cancer cells by candidaspongiolide,
a novel sponge polyketide. J Natl Cancer Inst 100: 1233–1246.
22. Travis WD, Garg K, Franklin WA, Wistuba II, Sabloff B, et al. (2006)
Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical impor-
tance and research relevance of the 2004 World Health Organization pathologic
criteria. J Thorac Oncol 1: S13–19.
23. Zhou YH, Hess KR, Liu L, Linskey ME, Yung WK (2005) Modeling prognosis
for patients with malignant astrocytic gliomas: quantifying the expression of
multiple genetic markers and clinical variables. Neuro Oncol 7: 485–494.
Prognostic Value of P-PKR and P-eIF2a
PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e24855